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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common human malignancies in the world, and
its prognosis is generally poor. Epigenetic alteration such as DNA methylation has been shown to be important in
the development of human cancers including HCC. Here, we analyzed the methylation status of ZAR1, which has
been reported to be aberrantly methylated in a few human cancers.
Methods: We investigated the methylation status of ZAR1 in 88 HCV-positive HCC and matched nontumorous liver
tissue samples and 4 normal liver tissue samples used as a control using MassARRAY EpiTYPER. Further statistical
analysis was performed to determine the relationship between methylation level and patient clinicopathological
features and prognosis.
Results: CpG islands in ZAR1 exon 1 showed a higher methylation level in all 88 HCC than in nontumorous tissues.
The hypermethylation group, whose cancer tissues showed a twofold or higher methylation level compared with
nontumorous tissues, showed a significantly higher serum AFP (p = 0.018) and lower serum albumin (p = 0.001) and
single rather than multiple tumors (p = 0.031) compared with the hypomethylation group. Multivariate regression
analyses were performed to identify which of the following factors were the predictors of the hypermethylation group:
serum albumin, AFP, and tumor multiplicity. This study showed that patients who had Zar1 hypermethylation
in the HCC tissues had a significantly lower serum albumin level than those in the hypomethylation group
(p = 0.007).
Conclusion: Although it is still unknown how ZAR1 hypermethylation affects HCC development, it could be a
potential marker to detect HCV-related HCC.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common human malignancies in the world. Despite the
fact that diagnosis and treatment have been established
for HCC, the prognosis is generally poor. Even after liver
resection, 25%, 50%, and 80% of HCC patients suffer re-
lapses within 1, 2, and 5 years, respectively. Although
the incidence of nonBnonC-HCC has recently shown an
increasing trend, there still are many HCV-positive HCC
patients in Japan (Ikai et al. 2007; Makuuchi et al. 1998).
Although the molecular mechanisms of its pathogenesis
remain unclear, epigenetic alteration such as DNA
methylation has been shown to play an important role in
the development of human cancers (Shinojima et al.
2010; Kawashima et al. 2012; Watanabe et al. 2011). In
addition, aberrant DNA methylation of promoter CpG
islands of many genes has been reported for HCC.
Methylation of promoter CpG islands of the tumor sup-
pressor genes has been reported. Genes such as p16,
p15, GSTP1, SOCS-1, RASSF1A, and APC play an im-
portant role in HCC development (Narimatsu et al.
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2004; Yang et al. 2003; Tischoff & Tannapfel 2008).
These genes are involved in the regulation of the cell cycle,
xenobiotic metabolism, suppression of cytokine signaling,
apoptosis, and cell migration. Most DNA methylation
studies have concentrated on genes mainly inactivated by
hypermethylation of normally unmethylated CpG islands
containing promoter regions. However, some researchers
have shown that CpG hypermethylation in nonpromoter
regions is sometimes associated with the upregulation of
gene expression (Smith et al. 2007). Shinojima et al. and
Watanabe et al. recently reported aberrant methylation in
candidate human genomic regions that was identified
through the analysis of skin tumor-specific differentially
methylated regions in mouse models using the restriction
landmark genomic scanning (RLGS) method. They exam-
ined differentially methylated regions in the exon of zygote
arrest 1 (ZAR1) that had never been linked to aberrant
methylation in melanomas and brain tumors (Shinojima
et al. 2010; Watanabe et al. 2011). Here, we detected aber-
rant methylation of the nonpromoter region of ZAR1 in
hepatitis C virus-positive HCC tissues compared with
nontumorous liver and metastatic liver cancer tissues.
Results and discussion
The methylation level of CpG islands in ZAR1 exon 1
(RLGS spot 5D52) was analyzed in 88 HCV-positive HCC
and 4 normal liver tissues, which were circumjacent to
colon cancer liver metastasis. The average methylation
level of all CpG sites in Zar1 in each individual was calcu-
lated, and 67 of 88 cases showed a significantly higher
methylation level in HCC than in nontumorous tissue
(p < 0.05) (Figure 1). The average methylation level of each
CpG site in Zar1 of all 88 cases are shown in Figure 2. All
CpG sites showed a significantly higher methylation
level in HCC than in the matched nontumorous tissues
(p < 0.05). Because it is already known that HCV-positive
nontumorous tissues undergo some epigenetic changes,
we also compared the methylation level of Zar1 in normal
liver tissues with that in HCV-positive nontumorous
tissues; however, no difference was found between the
tissues (data not shown).
The hypermethylation group was defined as the sam-
ple set in which patients’ cancer tissues showed a two-
fold or higher methylation level of ZAR1 compared with
nontumorous liver tissues. A total of 22 and 66 patients
were enrolled in hypermethylation hypomethylation groups,
respectively. When the background clinicopathological fea-
tures of the hypermethylation and hypomethylation groups
were compared using univariate analysis, there were signifi-
cant differences in levels of serum AFP (p = 0.018) and
albumin (p = 0.001) and tumor multiplicity (p = 0.031)
(Table 1). Multivariate regression analyses were performed
to identify which of the following factors were the predic-
tors of hypermethylation: serum albumin, AFP, and tumor
multiplicity. The presence of low serum albumin level in-
creased the risk for hypermethylation (p = 0.007) (Table 2).
These results demonstrated that DNA methylation
levels of ZAR1 were significantly different between HCV-
related HCC and nontumorous tissues. Most studies on
the analysis of DNA methylation in cancer genomes have
focused on promoter CpG island methylation and exam-
ined only restricted sets of CpG sites in their target
regions. To identify genome-wide aberrant methylation
in mouse skin cancer tissues, we previously performed
RLGS analysis and then confirmed the results using
MassARRAY EpiTYPER. The RLGS method can semi-
quantitatively detect the change in methylation level of
NotI in global genomic regions, including the regions out-
side the promoter. MassARRAY EpiTYPER can quantita-
tively analyze the methylation level of CpG sites by base-
specific cleavage in combination with MALDI-TOF-MS
detection. Using these methods, we were able to detect a
differentially methylated region in the exon of ZAR1 that
had never been identified as an aberrantly methylated re-
gion in clinical HCC tissue samples (Shinojima et al. 2010;
Smiraglia et al. 2007). Our findings clearly showed that ab-
errant hypermethylation of the ZAR1 nonpromoter region
was common in many HCV-related HCC tissues.
ZAR1 is an ovary-specific maternal factor that has crit-
ical importance in the initiation of embryogenesis (Wu
et al. 2003). Mouse and human ZAR1 protein contain 361
and 424 amino acids, respectively, and have 59% similarity
in amino acid sequence. Although the ZAR1 protein
is not a member of any characterized protein family, it
contains an atypical plant homeodomain (PHD) finger in
its C-terminus. PHDs are found in two major classes of
proteins, such as transcriptional activators, repressors,
or cofactors and subunits of complexes that modulate
chromatin (Wu et al. 2003). ZAR1 may be a transcrip-
tional regulator, and the conserved ZAR1 C-terminus
is probably important for its function. Shinojima et al.
analyzed malignant melanomas and reported that tumor-
specific methylation of CpG islands in ZAR1 that were
located downstream from the promoter region was associ-
ated with an increased expression level of the ZAR1 tran-
script. Although they transfected the full-length ZAR1
cDNA plasmid into normal melanocytes and also
performed knock down of ZAR1 expression in melanoma
cells using siRNA, no differences were observed in either
the cell growth rate or the morphology of the transfected
cells (Shinojima et al. 2010). In the present study, the
hypermethylation group, whose cancer tissues showed a
twofold or higher methylation level compared with
nontumorous liver tissues, showed a significantly higher
level of serum AFP (p = 0.018) and lower level of serum
albumin (p = 0.001) compared with the hypomethylation
group, using univariate analysis. In addition, all the pa-
tients in the hypermethylation group developed only
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single, but not multiple, tumors (p = 0.031). Multivariate
regression analyses were performed to identify the predic-
tors of the hypermethylation group. The patient with
low serum albumin level had an increased risk for
hypermethylation (p = 0.007). In general, it was already
known that a high serum AFP level and low serum albu-
min level are associated with development and poor prog-
nosis of HCC (Tateyama et al. 2011; Ueno et al. 2002).
Albumin is a group of proteins produced mainly in the
liver. Because the method for measurement of albumin
concentration is simple and easy, the serum albumin level
has been used as a prognostic factor following liver resec-
tion. However, owing to the long half-life of albumin, it is
not a sensitive marker to detect events changing over a
short period (Shirabe et al. 2011; Horino et al. 2012). In this
study, the mean values of methylation level of all CpG sites
Figure 1 Average methylation level of all CpG sites in Zar1 in each individual. A total of 67 of 88 cases showed a significantly higher
methylation level in HCC than in matched nontumorous tissues (p < 0.05). Data are shown as mean ± SD.
Figure 2 Average methylation level of each CpG site in Zar1 in HCC and nontumorous liver tissues. Open bars indicate nontumorous
tissues, and filled bars indicate HCC tissues. All CpG sites showed a significantly higher methylation level in HCC than in nontumorous tissues
(p < 0.05). Data are shown as mean ± SD.
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in HCC tissues were higher, and the presence of low serum
albumin level increased the risk for hypermethylation
(p = 0.007). For these reasons, it is suggested that ZAR1
hypermethylation could be a novel and good marker to
detect HCC and also could be a potential marker for
HCC prognosis.
ZAR1 mRNA expression was not detected in any of
the tissue specimens in this study. There is a possible
explanation for this result. The aberrant hypermethylation
of ZAR1 may be the result of a secondary effect of the
tumorigenesis process, or the methylation level of Zar1
exon 1 may be involved in the regulation of other genes
distant from Zar1. Further studies are needed to
understand the role of hypermethylation of the Zar1 gen-
omic region in HCC development.
Conclusions
This study showed that the methylation level of the Zar1
genomic region is higher in HCV-related HCC than
in nontumorous tissues and that patients with Zar1
hypermethylation had a significantly lower serum albumin
level than those from the hypomethylation group. Al-
though it is still unknown how ZAR1 hypermethylation
affects HCC development, it could be a marker for HCV-
related HCC and also could be a potential marker for
predicting HCC prognosis.
Methods
Patients and tissue samples
Eighty-eight hepatitis C virus-positive HCC and matched
nontumorous tissue and four normal liver tissues, which
were circumjacent to tissues of metastatic liver cancer,
Table 1 Comparison of clinicopathological features between the 2 groups
Variable Hypermethylation group n = 22 (%) Hypomethylation group n = 66 (%) P
Gender M 17 (77.3) 58 (87.9) 0.225
F 5 (22.7) 8 (12.1)
Age (y)a 65.8 (50.0-78.0) 68.5 (50.0-78.0) 0.07
ICG15R (%) < 10 6 (27.3) 26 (39.4) 0.306
≧10 16 (72.7) 40 (60.6)
Alb (g/dl) < 3.5 9 (40.9) 6 (9.1) 0.001
≧3.5 13 (59.1) 60 (90.9)
AST (U/l) < 40 7 (31.8) 21 (31.8) 1.000
≧40 15 (68.2) 45 (68.2)
ALT (U/l) < 40 9 (40.9) 27 (40.9) 1.000
≧40 13 (59.1) 39 (59.1)
T.Bil (mg/dl) < 1.2 20 (90.9) 59 (89.4) 0.839
≧1.2 2 (9.1) 7 (10.6)
AFP (ng/ml) < 20 8 (36.4) 42 (63.6) 0.018
≧20 14 (63.6) 24 (36.4)
non-LC 10 (45.5) 41 (62.1) 0.170
LC 12 (54.5) 25 (37.9)
Vascular invasion (+) 10 (45.5) 43 (65.2) 0.102
(−) 12 (54.5) 23 (34.8)
Tumor multiplicity single 22 (100) 54 (81.8) 0.031
multiple 0 (0) 12 (18.2)
Liver damage A 15 (68.2) 38 (57.6) 0.379
B 7 (31.8) 28 (42.4)
Recurrence (+) 19 (86.4) 52 (78.8) 0.436
(−) 3 (13.6) 14 (21.2)
aData are given as median (range).
ICG15R, indocyanin green retention rate at 15 min; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T.Bil, total bilirubin; AFP, alpha
fetoprotein; LC, liver cirrhosis.
Table 2 Independent risk factors predicting
hypermethylation in multivariate logistic regression
analysis
Odds ratio 95% CI p
Alb (g/dl) < 3.5 5.921 1.643-21.335 0.007
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were obtained from the Nihon University Hospital, Japan,
from 1995 to 2010. Informed consent was obtained from
all patients. All liver tissue specimens were immediately
frozen in liquid nitrogen and stored at −80°C until
use. Nontumorous tissues were excised with sufficient
margins from the cancer. This study was approved by
the Institutional Review Boards of Nihon University
School of Medicine.
DNA extraction and bisulfite treatment
DNA was extracted using the standard phenol–chloro-
form purification method or a QIAamp DNA Mini Kit
(Qiagen, Valencia, CA, USA). Bisulfite modification of
DNA was performed using an EZ DNA Methylation
Gold Kit (Zymo Reseach, Orange, CA, USA). Bisulfite-
treated genomic DNA was amplified using HotStar Taq
Polymerase (Qiagen) for 15 min at 94°C followed by 45 -
cycles of 20 s at 94°C, 30 s at 56°C, and 1 min at 72°C,
with a 3-min final extraction at 72°C. The polymerase
chain reaction (PCR) products obtained were subjected to
gel electrophoresis and then measured using Sequenom
MassARRAY.
Quantitative methylation analysis using base-specific
cleavage and matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF-MS)
A Sequenom MassARRAY quantitative DNA methylation
analysis was performed (Ehrich et al. 2005) using the
MassARRAY Compact System. This system is based
on mass spectrometry (MS) for the detection and quanti-
tative analysis of DNA methylation using homogeneous
MassCLEAVE (hMC), base-specific cleavage, and matrix-
assisted laser desorption/ionization time-of-flight MS
(MALDI-TOF MS) (Ehrich et al. 2005). The ZAR1 primer
was designed using Methyl Primer ExpressW Software to
span the closely adjacent DMRs or the GC rich region, as
indicated. The primers used for the quantitative ZAR1
methylation analysis were designed to anneal to the
374-bp bisulfite-treated fragment for the MassARRAY
EpiTYPER (Sequenom, San Diego, CA, USA). The reverse
primer has a T7-promoter tag for in vitro transcription
(50-cagtaatacgactcactatagggagaaggct-30), and the forward
primer is tagged with a decamer to balance the
temperature (Tm) (5'-aggaagagag-30). These primers were
purchased from Operon (Tokyo, Japan). PCR amplifica-
tion was performed using HotStar Taq Polymerase
(Qiagen) in a 5-μl reaction volume using PCR primer
at a final concentration of 200 nM and 1 μl of bisulfite-
treated DNA (~20 ng/ml). After treatment with shrimp
alkaline phosphatase, 2-μl aliquots of the PCR products
were used as a template for in vitro transcription
and RNase A cleavage for the T-reverse reaction, as
described in the manufacturer’s instructions (Sequenom
hMC). The samples were desalted and spotted on a
384-pad SpectroCHIP (Sequenom) using a MassARRAY
nanodispenser (Samsung, Seoul, Korea) followed by spec-
tral acquisition on a MassARRAY Analyzer Compact
MALDI-TOF MS (Sequenom). The resultant methyla-
tion calls were analyzed using EpiTYPER software v1.0
(Sequenom) to generate quantitative measurements for
each CpG site or an aggregate of multiple CpG sites. A
standard curve of quantitative DNA methylation analysis
was constructed using 0%, 50%, and 100% methylated
samples. The amplified DNA was not methylated at all
in any of the CpG sites and was used as unmethylated
(0%) control. M.SssI double-treated DNA was prepared
according to the manufacture’s protocols (New England
Biolabs, Ipswich, MA, USA) at 37°C for 1 h followed by
inactivation at 65°C for 20 min for 100% methylation sam-
ples. By mixing equal amounts of 0% and 100% control
samples, the 50% methylation samples were prepared. The
standard curve was fitted, and methylation levels were
adjusted and quantified.
Statistical analysis
Comparison of clinicopathological features between the
hypermethylation and hypomethylation groups was ana-
lyzed by Fisher’s exact test or Mann–Whitney U test.
Methylation levels of HCV-related HCC and metastatic
liver cancer tissues were compared using the t-test. Stat-
istical analysis was performed using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA). Differences were consid-
ered significant at p < 0.05.
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